Vir Biotechnology, Inc. (VIR)
Nasdaq: VIR · Biological Products, (No Diagnostic Substances) · San Francisco, CA · filing with the SEC since 2018
Who owns Vir Biotechnology, Inc.
As filed with the SECHolders of 5% or more
5
Blackrock, Inc. holds 12.4% of Common Stock, as its SCHEDULE 13G/A filed Oct 27, 2026 says.
Directors and officers
14
report now, of 31 people on the record since 2019. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 27, 2026 · Common Stock · 10.8% in Apr 28, 2025
Robert Nelsen
SCHEDULE 13D/A · filed Mar 3, 2026 · Common Stock, $0.0001 par value
Vanguard Portfolio Management
SCHEDULE 13G/A · filed Jul 31, 2026 · Common Stock · 5.79% in Apr 29, 2026
SB Investment Advisers (UK) Limited
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.0001 par value · 9.4% in Feb 17, 2026
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What VIR reports owning in othersstakes of 5% or more, and other ties
5 subsidiaries in 3 countries, from the list filed with the 10-K filed Feb 23, 2026.
Insider tradesForm 4
30sales
0purchases
30sales on a scheduled plan
7people selling
$2.9Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 4, 2025 to Nov 4, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 4, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window9 of 51 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Svf Endurance (Cayman) Ltd | 10% owner | 3 | $4.1M | 3 | 0 | $0 |
| Sato Vicki L | director | 9 | $1.5M | 9 | 0 | $0 |
| Softbank Vision Fund (Aiv M1) L.P. | 10% owner | 2 | $1.2M | 2 | 0 | $0 |
| De Backer Marianne | President and CEO | 3 | $900,000 | 3 | 0 | $0 |
| De Verneuil Vanina | EVP, General Counsel, Corp Sec | 6 | $300,000 | 6 | 0 | $0 |
| O'Byrne Jason | EVP & Chief Financial Officer | 3 | $100,000 | 3 | 0 | $0 |
| Sabatini Brent | SVP, Chief Accounting Officer | 5 | $100,000 | 5 | 0 | $0 |
| Eisner Mark | EVP and Chief Medical Officer | 3 | $0 | 3 | 0 | $0 |
| Napolitano Janet | director | 1 | $0 | 1 | 0 | $0 |